[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1119702T1 - Στερεα μορφη παραγωγου διυδρο-πυριδο-οξαζινης - Google Patents

Στερεα μορφη παραγωγου διυδρο-πυριδο-οξαζινης

Info

Publication number
CY1119702T1
CY1119702T1 CY20171101078T CY171101078T CY1119702T1 CY 1119702 T1 CY1119702 T1 CY 1119702T1 CY 20171101078 T CY20171101078 T CY 20171101078T CY 171101078 T CY171101078 T CY 171101078T CY 1119702 T1 CY1119702 T1 CY 1119702T1
Authority
CY
Cyprus
Prior art keywords
pyrido
dyydro
oxazine
producer
solid form
Prior art date
Application number
CY20171101078T
Other languages
English (en)
Inventor
Konstanze Hurth
Christoph KALIS
Karen KAMMERTOENS
Nicolas Soldermann
Frédéric ZECRI
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51019963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119702(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1119702T1 publication Critical patent/CY1119702T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η ευρεσιτεχνία αναφέρεται σε μια άνυδρη κρυσταλλική μορφή της (1,1-διοξο-εξαϋδρο-1λάμδα*6*-θειοπυραν-4-υλ) - {(S)-3-[1-(6-μεθοξυ-5-μεθυλο-πυριδινο-3-υλ) -2,3-διυδρο-1Η-πυριδο[3,4-b] [1,4]οξαζιν-7-υλοξυ]-πυρρολιδιν-1-υλ}-μεθανόνης• φαρμακευτικές συνθέσεις και συνδυασμούς που περιλαμβάνουν αυτές τις μορφές όπως επίσης και σε μεθόδους χρήσης αυτών των μορφών, συμπεριλαμβανομένων των φαρμακευτικών τους συνθέσεων και συνδυασμών για τη θεραπεία νόσων.
CY20171101078T 2012-11-26 2017-10-13 Στερεα μορφη παραγωγου διυδρο-πυριδο-οξαζινης CY1119702T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GC201222895 2012-11-26
IR1391307213 2012-12-04
PCT/IB2013/060412 WO2014102630A1 (en) 2012-11-26 2013-11-26 Solid form of dihydro-pyrido-oxazine derivative

Publications (1)

Publication Number Publication Date
CY1119702T1 true CY1119702T1 (el) 2018-06-27

Family

ID=51019963

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101078T CY1119702T1 (el) 2012-11-26 2017-10-13 Στερεα μορφη παραγωγου διυδρο-πυριδο-οξαζινης

Country Status (22)

Country Link
EP (1) EP2928896B1 (el)
KR (1) KR102184069B1 (el)
CN (1) CN104870451B (el)
AU (1) AU2013368997B8 (el)
BR (1) BR112015009870A2 (el)
CA (1) CA2891521A1 (el)
CL (1) CL2015001409A1 (el)
CY (1) CY1119702T1 (el)
DK (1) DK2928896T3 (el)
GT (1) GT201500124A (el)
IL (1) IL238889B (el)
MX (1) MX366342B (el)
NZ (1) NZ706865A (el)
PE (1) PE20150946A1 (el)
PH (1) PH12015501052A1 (el)
PL (1) PL2928896T3 (el)
PT (1) PT2928896T (el)
SG (1) SG11201503410VA (el)
TN (1) TN2015000128A1 (el)
TW (1) TW201422625A (el)
WO (1) WO2014102630A1 (el)
ZA (1) ZA201502350B (el)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY170922A (en) 2011-12-22 2019-09-18 Novartis Ag Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
HUE067912T2 (hu) 2018-08-13 2024-11-28 Hoffmann La Roche Új heterociklusos vegyületek, mint monoacil-glicerin-lipáz inhibitorok
CA3151516A1 (en) 2019-09-12 2021-03-18 F. Hoffmann-La Roche Ag 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU11248A1 (ru) 1927-03-29 1929-09-30 В.С. Григорьев Способ очистки антрацена
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
DE3372965D1 (en) 1982-07-23 1987-09-17 Ici Plc Amide derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
TW225528B (el) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
EP2163546B1 (en) 1995-03-30 2016-06-01 Pfizer Products Inc. Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
CZ1598A3 (cs) 1995-07-06 1998-04-15 Novartis Ag Pyrrolopyrimidiny a způsoby jejich přípravy
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
EE05289B1 (et) 1996-04-12 2010-04-15 Warner-Lambert Company Türosiinkinaaside pöördumatud inhibiitorid, farmatseutiline kompositsioon, kasutamine
AU2912997A (en) 1996-06-24 1998-01-14 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
ATE247724T1 (de) 1996-09-06 2003-09-15 Obducat Ab Verfahren für das anisotrope ätzen von strukturen in leitende materialien
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
PT1367057E (pt) 1996-11-18 2008-12-04 Biotechnolog Forschung Gmbh Epotilonas e e f
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
NZ506742A (en) 1998-02-25 2003-09-26 Sloan Kettering Inst Cancer Synthesis of desoxyepothilones and hydroxy acid derivative intermediates
CN1152031C (zh) 1998-08-11 2004-06-02 诺瓦提斯公司 具有血管生成抑制活性的异喹啉衍生物
KR100851418B1 (ko) 1998-11-20 2008-08-08 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
HU228999B1 (en) 2000-11-07 2013-07-29 Novartis Ag Indolylmaleimide derivatives
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
PE20040079A1 (es) 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
NZ540427A (en) 2002-12-09 2008-04-30 Univ Texas Methods for selectively inhibiting janus tyrosine kinase 3 (Jak3)
BRPI0506817A (pt) 2004-01-12 2007-05-29 Cytopia Res Pty Ltd inibidores seletivos de quinase
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JP2009507072A (ja) * 2005-09-07 2009-02-19 ラボラトワール セローノ ソシエテ アノニム 子宮内膜症の処置のためのｐｉ３ｋ阻害剤
GB0620059D0 (en) * 2006-10-10 2006-11-22 Ucb Sa Therapeutic agents
MY170922A (en) * 2011-12-22 2019-09-18 Novartis Ag Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives

Also Published As

Publication number Publication date
KR102184069B1 (ko) 2020-11-30
PT2928896T (pt) 2017-10-25
CA2891521A1 (en) 2014-07-03
GT201500124A (es) 2016-03-01
IL238889A0 (en) 2015-07-30
EP2928896B1 (en) 2017-07-19
SG11201503410VA (en) 2015-05-28
TW201422625A (zh) 2014-06-16
MX366342B (es) 2019-07-05
TN2015000128A1 (en) 2016-10-03
WO2014102630A1 (en) 2014-07-03
AU2013368997B2 (en) 2015-09-24
MX2015006650A (es) 2015-08-10
PH12015501052A1 (en) 2015-07-27
CN104870451B (zh) 2017-07-07
NZ706865A (en) 2016-04-29
AU2013368997A8 (en) 2015-10-08
ZA201502350B (en) 2017-08-30
BR112015009870A2 (pt) 2017-12-05
AU2013368997A1 (en) 2015-04-30
PL2928896T3 (pl) 2018-01-31
AU2013368997B8 (en) 2015-10-08
HK1209419A1 (en) 2016-04-01
EP2928896A1 (en) 2015-10-14
CN104870451A (zh) 2015-08-26
IL238889B (en) 2021-03-25
KR20150091047A (ko) 2015-08-07
DK2928896T3 (da) 2017-11-06
CL2015001409A1 (es) 2015-07-24
PE20150946A1 (es) 2015-06-28

Similar Documents

Publication Publication Date Title
ECSP22091792A (es) Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroplastos
ECSP15031579A (es) Lactamas Fusionadas de Arilo y Heteroarilo
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
EA201100161A1 (ru) Производные хинуклидина карбоната и их медицинские композиции
EA201100299A1 (ru) Органические соединения
CY1120881T1 (el) Ανταγωνιστες υποδοχεα 5-ητ3
CY1120204T1 (el) Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο
EA201170772A1 (ru) Органические соединения
UA109464C2 (uk) Спірооксіндольні антагоністи mdm2
EA201390381A1 (ru) Триазиноксадиазолы
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
MX339899B (es) Compuestos de triazolopiridina como inhibidores de pim cinasa.
EA201170356A1 (ru) Полиморфные и аморфные формы лакозамида и аморфные композиции
EA201690521A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
EA201590381A1 (ru) Замещенные пиразолы, используемые в качестве блокаторов кальциевых каналов n-типа
MX348451B (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12.
EA201290744A1 (ru) Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов
IN2014CN03597A (el)
EA201600121A1 (ru) Новые индольные и пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их
CU24398B1 (es) 3-(piperidin,pirrol o azetidin)-indoles sustituidos útiles como inhibidores rorc2
EA201391797A1 (ru) 3-спироциклические пиперидиновые производные в качестве агонистов грелиновых рецепторов
EA201600122A1 (ru) Новые изоиндолиновые или изохинолиновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA201590379A1 (ru) Пирролопиразолы, используемые в качестве блокаторов кальциевых каналов n-типа
CY1119702T1 (el) Στερεα μορφη παραγωγου διυδρο-πυριδο-οξαζινης